Cargando…
P07 Toxicokinetic profile of VRP-034
BACKGROUND: Polymyxin B (PMB) can be an effective option for treating resistant Gram-negative pathogens, however, its use is severely compromised by its’ dose-limiting toxicity. VRP-034, a novel formulation of PMB, has previously reported a favourable safety profile compared with marketed PMB (Roy e...
Autores principales: | Murkunde, Yogeshkumar Vishnupant, Chaudhary, Saransh, Vishwakarma, Kamlesh Kumar, Aggarwal, Anmol, Chilbule, Rahul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849398/ http://dx.doi.org/10.1093/jacamr/dlac004.006 |
Ejemplares similares
-
P06 Pharmacokinetics and renal accumulation of VRP-034
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022) -
P05 In vivo efficacy of VRP-034 in lung and thigh infection models
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022) -
Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021) -
P034. Technostress and primary headache: psychosocial risk
por: Pucci, Ennio, et al.
Publicado: (2015) -
P034 Inter-scorer concordance impacts MSLT results
por: Eriksson, N, et al.
Publicado: (2021)